Congratulations to Dr Rajendran and the teams at Ascension Alexian Brothers Medical Center and Radiation Oncology Consultants for their recent approval to partake in this imaging study. We look forward to our collaboration and hope the outcomes of this trial can shed light on overcoming challenges in imaging interpretation for patients with brain metastasis that have undergone radiosurgery.
Ascension Alexian Brothers Medical Center and Radiation Oncology Consultants have recently gained approval to participate in Radiopharm Theranostics' RAD 101 PIIb imaging trial. With over 20 years of experience in Stereotactic Radiosurgery, we are able to provide a clinical trial for imaging brain metastases that have recurred or are undergoing radiation necrosis. RAD 101 is a novel imaging small molecule that targets fatty acid synthase (FASN), which is overexpressed in many solid tumors including brain metastasis. The open-label, single dose, single arm multicenter US study aims to establish the imaging performance of 18F-tagged RAD 101, in participants with suspected recurrent brain metastases from solid tumors of different origins. Enrolment is anticipated to commence in Q4 2024. We hope to provide our patients with the most cutting edge theranostics and radiopharmaceuticals.